|
AGEN | Agenus Inc |
|
|
AGEN | Agenus Inc |
| Biological Products (no Diagnostic Substances) |
| Book value per $ invested | $ -0.16 |
| Leverage | 217.21% |
| Market Cap | $ 1.7B |
| PE | 0.00 |
| Dividend Yield | 0.00% |
| Profit | $ -40.2m |
| Margin | -21.52% |
Agenus Inc., a clinical-stage immuno-oncology company, discovers and develops immuno-oncology products in the United States and internationally. The company is headquartered in Lexington, Massachusetts.